Wolverine Trading’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $216K | Buy |
+16,700
| New | +$223K | ﹤0.01% | 4840 |
|
|
2025
Q1 | – | Sell |
-18,600
| Closed | -$559K | – | 5495 |
|
|
2024
Q4 | $559K | Buy |
18,600
+3,100
| +20% | +$65.6K | ﹤0.01% | 3275 |
|
|
2024
Q3 | $242K | Buy |
15,500
+2,200
| +17% | +$39.9K | ﹤0.01% | 3857 |
|
|
2024
Q2 | $228K | Sell |
13,300
-14,000
| -51% | -$246K | ﹤0.01% | 3710 |
|
|
2024
Q1 | $427K | Buy |
27,300
+16,000
| +142% | +$235K | ﹤0.01% | 2999 |
|
|
2023
Q4 | $169K | Sell |
11,300
-2,800
| -20% | -$37.5K | ﹤0.01% | 3952 |
|
|
2023
Q3 | $228K | Sell |
14,100
-10,100
| -42% | -$291K | ﹤0.01% | 3612 |
|
|
2023
Q2 | $975K | Buy |
24,200
+12,900
| +114% | +$801K | ﹤0.01% | 2026 |
|
|
2023
Q1 | $658K | Sell |
11,300
-22,500
| -67% | -$1.8M | ﹤0.01% | 2259 |
|
|
2022
Q4 | $2.48M | Buy |
33,800
+8,600
| +34% | +$647K | ﹤0.01% | 1259 |
|
|
2022
Q3 | $1.94M | Buy |
25,200
+3,200
| +15% | +$250K | ﹤0.01% | 1435 |
|
|
2022
Q2 | $1.59M | Sell |
22,000
-5,000
| -19% | -$377K | ﹤0.01% | 1554 |
|
|
2022
Q1 | $2.27M | Sell |
27,000
-6,600
| -20% | -$486K | ﹤0.01% | 1651 |
|
|
2021
Q4 | $2.68M | Buy |
33,600
+1,700
| +5% | +$171K | ﹤0.01% | 1614 |
|
|
2021
Q3 | $3.71M | Sell |
31,900
-25,100
| -44% | -$3.79M | ﹤0.01% | 1548 |
|
|
2021
Q2 | $12.8M | Buy |
57,000
+38,600
| +210% | +$7.51M | 0.02% | 603 |
|
|
2021
Q1 | $2.31M | Buy |
+18,400
| New | +$2.91M | ﹤0.01% | 1799 |
|
|
2020
Q4 | – | Sell |
-64,500
| Closed | -$7.03M | – | 5257 |
|
|
2020
Q3 | $7.03M | Sell |
64,500
-12,000
| -16% | -$960K | 0.02% | 680 |
|
|
2020
Q2 | $4.41M | Sell |
76,500
-79,500
| -51% | -$5.23M | 0.01% | 879 |
|
|
2020
Q1 | $10.9M | Buy |
156,000
+51,000
| +49% | +$4.03M | 0.03% | 397 |
|
|
2019
Q4 | $8.95M | Buy |
105,000
+25,800
| +33% | +$2.08M | 0.02% | 726 |
|
|
2019
Q3 | $5.82M | Buy |
79,200
+22,300
| +39% | +$1.78M | 0.02% | 785 |
|
|
2019
Q2 | $3.6M | Buy |
+56,900
| New | +$2.88M | 0.01% | 1114 |
|
|
2019
Q1 | – | Sell |
-18,800
| Closed | -$617K | – | 5056 |
|
|
2018
Q4 | $617K | Sell |
18,800
-9,000
| -32% | -$329K | ﹤0.01% | 2439 |
|
|
2018
Q3 | $1.46M | Buy |
27,800
+12,100
| +77% | +$482K | ﹤0.01% | 1960 |
|
|
2018
Q2 | $342K | Hold |
15,700
| – | – | ﹤0.01% | 3598 |
|
|
2018
Q1 | $342K | Sell |
15,700
-8,800
| -36% | -$189K | ﹤0.01% | 3598 |
|
|
2017
Q4 | $495K | Buy |
+24,500
| New | +$472K | ﹤0.01% | 3010 |
|
|
2017
Q1 | – | Sell |
-14,200
| Closed | -$111K | – | 4771 |
|
|
2016
Q4 | $111K | Buy |
+14,200
| New | +$114K | ﹤0.01% | 4026 |
|
|
2016
Q3 | – | Sell |
-18,900
| Closed | -$215K | – | 4952 |
|
|
2016
Q2 | $215K | Buy |
+18,900
| New | +$237K | ﹤0.01% | 3205 |
|
Other funds holding NVCR
SCM
N
QCM
Wolverine Trading's NVCR Position: Q1 2025 in Review
Wolverine Trading sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 9,799 shares — an estimated $223K sold.
Wolverine Trading first reported a position in NVCR in Q2 2016 and held it in 20 quarters. The position peaked at $4.48M in Q2 2021. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.
- Wolverine Trading reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
- Wolverine Trading sold 9,799 NovoCure shares in Q1 2025, an estimated $223K.
- Wolverine Trading first reported a position in NovoCure in Q2 2016 and held it in 20 quarters.
- Wolverine Trading's NovoCure position peaked at $4.48M in Q2 2021.
- 227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.
Based on Wolverine Trading's 13F filing for Q1 2025, filed 15 May 2025.